Morbid obesity leads to non-alcoholic fatty liver disease (NAFLD), and not all NAFLD cases benefit from weight loss e.g. after bariatric surgery. Our aim is to find out, which intrahepatic factors and / or biomarkers might be beneficial or can be identified as prognostic factors for remission of NAFLD after weight loss. As other factors such as the microbiome or muscle and fatty tissue also influence the development of obesity and liver diseases, it is planned to examine these parameters before and after bariatric surgery as well. Tissue biopsies will therefore be taken during the surgery, and blood as well as stool samples will be collected and compared for suitable biomarkers before and after the intervention.
Study Type
OBSERVATIONAL
Enrollment
204
Any bariatric operation that is considered as a standard procedure in bariatric surgery (i.e. sleeve gastrectomy, roux-en-y gastric bypass, mini-gastric / one anastomosis gastric bypass, redo and revisional bariatric surgery).
University of Bonn
Bonn, Germany
St. Franziskus-Hospital
Cologne, Germany
Changes of microbiome after bariatric surgery
Collection of stool sample before and after (3 and 6 months) the operation
Time frame: at time of operation, 3 and 6 months after the operation
Changes of microbiome after bariatric surgery
Collection of blood sample before and after (3 and 6 months) the operation
Time frame: at time of operation, 3 and 6 months after the operation
incidence of fatty liver in obese patients
Surgical liver biopsy during laparoscopy
Time frame: during the operation
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.